Related Experiment Videos
Differential induction of human monocyte transforming growth factor beta 1 production and its regulation by
C L Miller-Graziano1, D Zhu, K Kodys
1Department of Surgery, University of Massachusetts Medical Center, Worcester 01655.
We have previously shown that trauma patients' monocytes which are in vivo activated by multiple injury-induced mediators have elevated transforming growth factor-beta (TGF beta) bioactivity. Interleukin-4 (IL-4), a Th2 and B lymphocyte stimulatory factor, has been shown to inhibit monocyte production of a number of mediators both after lipopolysaccharide stimulation and after trauma-induced stimulation. However, IL-4 inhibitory effects appears to vary, depending on the mixture of inducing stimuli. Here we describe the in vitro IL-4 inhibition of human monocyte TGF beta bioactivity using several stimulation induction protocols: muramyl dipeptide stimulation alone, or after Fc gamma RI (CD64) cross-linking induction, interferon-gamma (IFN gamma) priming, or trauma-generated in vivo mediator induction. IL-4 suppressed both muramyl dipeptide-induced TGF beta bioactivity and TGF beta mRNA in a dose-dependent fashion and was most effective when IL-4 was administered at initiation of normal monocyte stimulation. Muramyl dipeptide (MDP)-induced increases in trauma patients' monocyte TGF beta bioactivity were also inhibited by high doses of IL-4 (25 ng/ml). Fc gamma RI cross-linking increased MDP-induced normal monocyte TGF beta bioactivity, but this increase could be consistently inhibited only by very high IL-4 concentrations (50 ng/ml). IL-4 did not consistently downregulate MDP-induced TGF beta bioactivity in IFN gamma-primed monocytes. IL-4 can suppress monocyte TGF beta production, as well as other monocyte mediators, but its efficiency depends on the stimuli combination present in the microenvironment.
We have previously shown that trauma patients' monocytes which are in vivo activated by multiple injury-induced mediators have elevated transforming growth factor-beta (TGF beta) bioactivity. Interleukin-4 (IL-4), a Th2 and B lymphocyte stimulatory factor, has been shown to inhibit monocyte production of a number of mediators both after lipopolysaccharide stimulation and after trauma-induced stimulation. However, IL-4 inhibitory effects appears to vary, depending on the mixture of inducing stimuli. Here we describe the in vitro IL-4 inhibition of human monocyte TGF beta bioactivity using several stimulation induction protocols: muramyl dipeptide stimulation alone, or after Fc gamma RI (CD64) cross-linking induction, interferon-gamma (IFN gamma) priming, or trauma-generated in vivo mediator induction. IL-4 suppressed both muramyl dipeptide-induced TGF beta bioactivity and TGF beta mRNA in a dose-dependent fashion and was most effective when IL-4 was administered at initiation of normal monocyte stimulation. Muramyl dipeptide (MDP)-induced increases in trauma patients' monocyte TGF beta bioactivity were also inhibited by high doses of IL-4 (25 ng/ml). Fc gamma RI cross-linking increased MDP-induced normal monocyte TGF beta bioactivity, but this increase could be consistently inhibited only by very high IL-4 concentrations (50 ng/ml). IL-4 did not consistently downregulate MDP-induced TGF beta bioactivity in IFN gamma-primed monocytes. IL-4 can suppress monocyte TGF beta production, as well as other monocyte mediators, but its efficiency depends on the stimuli combination present in the microenvironment.